Table S2 from The Pathognomonic FOXL2 C134W Mutation Alters DNA-Binding Specificity

List of protein-coding (pc) and non_coding (nc) genes differentially expressed (UP or DOWN) following induction of WT and MUT FOXL2 in polyA and ribodepleted RNA-seq datasets.</p

Supplementary Figures from The Pathognomonic FOXL2 C134W Mutation Alters DNA-Binding Specificity

File containing supplemental figures and legends</p

Supplementary Methods from The Pathognomonic FOXL2 C134W Mutation Alters DNA-Binding Specificity

Detailed supplemental methods of cell lines and cell culture, cell cycle synchronization and inducible expression of FOXL2, quantitative mass spectrometry analysis of induced FOXL2 expression, FOXL2 ChIP-seq analysis, RNA-seq analysis, and electrophoretic mobility shift assay.</p

Table S1 from The Pathognomonic FOXL2 C134W Mutation Alters DNA-Binding Specificity

RNA-seq (polyA and ribodepleted) RPKM matrix for protein coding genes from primary AGCT and SVOG3e derived isogenic cell lines.</p

Table S3 from The Pathognomonic FOXL2 C134W Mutation Alters DNA-Binding Specificity

Known transcription factor motifs enriched in shared and FOXL2 mutant-specific peaks predicted by Homer motif analysis.</p

Supplementary Figure S9 from Surface and Global Proteome Analyses Identify ENPP1 and Other Surface Proteins as Actionable Immunotherapeutic Targets in Ewing Sarcoma

Domain structure of ENPP1 and CDH11.</p

Supplementary Figures from Biallelic <i>Dicer1</i> Mutations in the Gynecologic Tract of Mice Drive Lineage-Specific Development of <i>DICER1</i> Syndrome–Associated Cancer

Supplementary Fig. S1-S11</p

Supplementary Data S1 from Surface and Global Proteome Analyses Identify ENPP1 and Other Surface Proteins as Actionable Immunotherapeutic Targets in Ewing Sarcoma

Log2 fold change values for proteins in EwS xenografts vs SuperMix.</p

Supplementary Data from Multiomics Characterization of Low-Grade Serous Ovarian Carcinoma Identifies Potential Biomarkers of MEK Inhibitor Sensitivity and Therapeutic Vulnerability

Supplementary Data from Multiomics Characterization of Low-Grade Serous Ovarian Carcinoma Identifies Potential Biomarkers of MEK Inhibitor Sensitivity and Therapeutic Vulnerabilit

Supplementary Figure S14 from Surface and Global Proteome Analyses Identify ENPP1 and Other Surface Proteins as Actionable Immunotherapeutic Targets in Ewing Sarcoma

ENPP1 is expressed at higher levels in non-metastatic EwS vs metastatic EwS.</p